- Home
- AUTL
as 04-23-2025 1:31pm EST
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 360.6M | IPO Year: | 2018 |
| Target Price: | $9.32 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $5.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $10,120,000 | Revenue Growth: | 496.00% |
| Revenue Growth (this year): | 277.74% | Revenue Growth (next year): | 221.89% |
Latest Autolus Therapeutics plc News
AUTL Breaking Stock News: Dive into AUTL Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Simply Wall St.
7 days ago
April 2025's Top Penny Stocks To Watch
TipRanks
21 days ago
Autolus Therapeutics price target lowered to $10 from $11 at Truist
GlobeNewswire
21 days ago
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
22 days ago
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
MT Newswires
23 days ago
Truist Adjusts Price Target on Autolus Therapeutics to $10 From $11, Maintains Buy Rating
GuruFocus.com
a month ago
What To Expect From Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings
GuruFocus.com
a month ago
Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings Call Highlights: Financial Growth Amid Rising Costs
Compare AUTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUTL Autolus Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.